

(19) World Intellectual Property Organization
International Bureau



1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100

BQ

(43) International Publication Date
21 February 2002 (21.02.2002)

PCT

(10) International Publication Number
WO 02/14519 A1

(51) International Patent Classification⁷: C12N 15/63,
15/85, 15/87, 15/00, 15/09, 15/63, 15/70, 15/74, 5/00,
5/02, A01N 43/04, A61K 31/70, G01N 33/00, A01K
67/00, 67/033, 67/027

(21) International Application Number: PCT/US01/25416

(22) International Filing Date: 14 August 2001 (14.08.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/638,648 14 August 2000 (14.08.2000) US

(71) Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US];
West 116th Street and Broadway, New York, NY 10027 (US).

(72) Inventors: STERN, David, M.; 63 Tanners Road, Great Neck, NY 11020 (US). SCHMIDT, Ann, Marie; 242 Haven Road, Franklin Lakes, NJ 07417 (US). YAN, Shi, Du; 60 Haven Avenue, Apt. 4-B, New York, NY 10032 (US). ZLOKOVIC, Berislav; 3345 Elmwood Avenue, Rochester, NY 14610 (US).

(74) Agent: WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- with sequence listing part of description published separately in electronic form and available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: A METHOD TO INCREASE CEREBRAL BLOOD FLOW IN AMYLOID ANGIOPATHY

(57) Abstract: The present invention provides a method for decreasing cerebral vasoconstriction in a subject suffering from chronic or acute cerebral amyloid angiopathy which comprises administering to the subject an inhibitor of receptor for advanced glycation endproduct (RAGE) in an effective amount to inhibit transcytosis of amyloid β peptides across the blood-brain barrier in the subject, thereby decreasing cerebral vasoconstriction in the subject. The invention further provides for a method for ameliorating neurovascular stress in a subject which comprises administering to the subject an effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE), so as to increase cerebral blood flow in the subject, thereby ameliorating neurovascular stress in the subject.



WO 02/14519 A1

A Method to Increase Cerebral Blood Flow In Amyloid
Angiopathy

5

The invention disclosed herein was made with Government support under Grant No. PO1AG16233 from the National Institutes of Health of the U.S. Department of Public Health. Accordingly, the U.S. Government has certain rights in this
10 invention.

Background of the Invention

Throughout this application, various publications are
15 referenced by number. Full citations for these publications may be found listed at the end of the specification immediately preceding the claims. The disclosures of these publications in their entireties are hereby incorporated by reference into this application in order to more fully
20 describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.

The pain of Alzheimer's disease results directly from the
25 memory loss and cognitive deficits suffered by the patient. These eventually result in the patient's loss of identity, autonomy, and freedom. As a step toward curing this disease, alleviating its symptoms, or retarding its progression, it would be desirable to develop a transgenic animal model
30 exhibiting the main debilitating phenotype of Alzheimer's disease, that is, memory loss, expressed concomitantly with the neuropathological correlates of Alzheimer's disease, for example, beta-amyloid accumulation, increased glial reactivity, and hippocampal cell loss.

-2-

It is estimated that over 5% of the U.S. population over 65 and over 15% of the U.S. population over 85 are beset with some form of Alzheimer's disease (Cross, A. J., Eur J Pharmacol (1982) 82:77-80; Terry, R. D., et al., Ann Neurol 5 (1983) 14:497-506). It is believed that the principal cause for confinement of the elderly in long term care facilities is due to this disease, and approximately 65% of those dying in skilled nursing facilities suffer from it.

- 10 Certain facts about the biochemical and metabolic phenomena associated with the presence of Alzheimer's disease are known. Two morphological and histopathological changes noted in Alzheimer's disease brains are neurofibrillary tangles (NFT) and amyloid deposits. Intraneuronal neurofibrillary
- 15 tangles are present in other degenerative diseases as well, but the presence of amyloid deposits both in the interneuronal spaces (neuritic plaques) and in the surrounding microvasculature (vascular plaques) seems to be characteristic of Alzheimer's. Of these, the neuritic plaques
- 20 seem to be the most prevalent (Price, D. L., et al., Drug Development Research (1985) 5:59-68). Plaques are also seen in the brains of aged Down's Syndrome patients who develop Alzheimer's disease.

-3-

Summary of the Invention

The present invention provides a method for decreasing cerebral vasoconstriction in a subject suffering from chronic
5 or acute cerebral amyloid angiopathy which comprises administering to the subject an inhibitor of receptor for advanced glycation endproduct (RAGE) in an effective amount to inhibit transcytosis of amyloid β peptides across the blood-brain barrier in the subject, thereby decreasing
10 cerebral vasoconstriction in the subject. The invention further provides for a method for ameliorating neurovascular stress in a subject which comprises administering to the subject an effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE), so as to increase
15 cerebral blood flow in the subject, thereby ameliorating neurovascular stress in the subject.

-4-

Brief Description of the Figures

Figures. 1A-1F. RAGE-dependent Amyloid beta ($A\beta$) binding to brain endothelium and *in vivo* transcytosis across the blood brain barrier (BBB) followed by rapid neuronal uptake of circulating $A\beta$ in mice. **Figure 1A** and **Figure 1B**, Binding to brain capillaries (a) and transport across the BBB (uptake by capillary-depleted brain expressed as cerebrovascular permeability product, PS) (b) of ^{125}I -labeled human $A\beta_{1-40}$ ($hA\beta_{1-40}^*$) and $A\beta_{1-42}$ ($hA\beta_{1-42}^*$), and murine $A\beta_{1-40}$ ($mA\beta_{1-40}^*$) infused into cerebral arterial circulation at 4 nM for 10 min via brain perfusion technique in the absence and presence of α -RAGE (40 mg/ml), sRAGE (40 nM), SR, scavenger receptor ligand - fucoidan (100 mg/ml), FNR5 (anti- β 1-integrin antibody, 40 mg/ml) or RHDS (40 nM); $hA\beta_{40-1}^*$ denotes ^{125}I -labeled scrambled peptide. **Figure 1C** and **Figure 1D**, Dose-dependent effect of α -RAGE (0.5 to 40 mg/ml) on brain capillary binding (c) and transport across the BBB (d) of ^{125}I - $A\beta_{1-40}$ ($hA\beta_{1-40}^*$). **Figure 1E**, Partial metabolic degradation of human $A\beta_{1-40}$ ($hA\beta_{1-40}^*$) and $A\beta_{1-42}$ ($hA\beta_{1-42}^*$) in brain parenchyma following 10 min of BBB transport of circulating ^{125}I -labeled peptides. **Figure 1F**, Immunocytochemical detection of $hA\beta_{1-40}$ with anti- $A\beta_{1-40}$ antibody (QCB) in brain parenchyma 10 min after its BBB transport in the absence (middle panel) and presence of α -RAGE, 40 mg/ml (right panel); control vehicle-infused brain is shown on a right panel. $n = 3$ to 5 mice per group. $*p < 0.01$.

Figures 2A-2D. Effect of RAGE blockade on $A\beta$ -induced cytokine expression and oxidant stress in brain after BBB transport of circulating $A\beta_{1-40}$. Expression of TNF- α mRNA (left) and protein (right) (**Figure 2A**), and immunocytochemical detection of IL-6 (**Figure 2B**) and HO-1

-5-

(*Figure 2C*) 15 min following transport of human $A\beta_{1-40}$ (4 nM) across the BBB in the presence or absence of α -RAGE (40 mg/ml) or sRAGE (40 nM) in the arterial inflow in a brain perfusion model. Vehicle-infused brains were also shown in *Figures 2A-2C* as control. Graphs in *Figures 2A-2C* illustrate image analysis of immunocytochemical experiments in which mice were treated with either vehicle, $A\beta_{1-40}$ alone, or $A\beta_{1-40}$ plus α -RAGE or sRAGE, as indicated. *Figure 2D*, Image analysis of mouse brains after 2 hrs of i.v. administration of $A\beta_{1-40}$ (4 nM) in the absence and presence of α -RAGE (40 mg/ml) or sRAGE (40 nM) infused 15 min prior to $A\beta_{1-40}$ infusion. n = 5 mice per group. *p < 0.01.

Figures 3A-3C. RAGE-dependent vasomotor effects of circulating $A\beta$. Decrease in CBF following i.v. administration of human $A\beta_{1-40}$ (4 nM) (*Figure 3A*) and effect of α -RAGE (40 mg/ml) (*Figures 3B-C*). α -RAGE (1-10 mg/ml) and sRAGE (40 nM) blocked CBF changes produced by murine or human $A\beta_{1-40}$; CBF values between 30 and 45 min after i.v. administration of peptides. sRAGE (40 nM) and IgG, lack of effect of an irrelevant IgG. n = 5 mice per group; *p < 0.01.

Figures 4A-4D. Effects of RAGE blockade on cerebral blood flow (CBF) in TgAPPsw+/- mice. *Figure 4A*, Baseline CBF values and arterial blood pressure in 9 months old TgAPPsw+/- mice and aged-matched control mice. *Figure 4B*, Significant increase in CBF in 9 months old TgAPPsw+/- mice following administration of α -RAGE (40 mg/ml); IgG, non-specific immunoglobulin *Figure 4C*, Image analysis of brains in TgAPPsw+/- mice for TNF- α , IL-6 and HO-1 2 hrs following treatment with either vehicle or α -RAGE (40 mg/ml). *Figure 4D*, Increased vascular expression of RAGE and $A\beta$ accumulation in Alzheimer's Disease (AD) brain. n = 5 mice per group; *p

< 0.01.

-7-

Detailed Description of the Invention

This invention provides for a method for decreasing cerebral vasoconstriction in a subject suffering from chronic or acute cerebral amyloid angiopathy which comprises administering to the subject an inhibitor of receptor for advanced glycation endproduct (RAGE) in an effective amount to inhibit transcytosis of amyloid β peptides across the blood-brain barrier in the subject, thereby decreasing cerebral vasoconstriction in the subject.

In one embodiment of the invention, the subject is a transgenic non-human animal or a human. In another embodiment of the invention, the non-human animal is a transgenic mouse which over-expresses mutant human amyloid beta precursor protein. In another embodiment of the invention, the subject suffers from Alzheimer's disease. In another embodiment of the invention, the chronic cerebral amyloid angiopathy is due to Alzheimer's disease, Down's syndrome, aging or angiopathy. In another embodiment of the invention, the acute cerebral amyloid angiopathy is due to head trauma, or stroke.

In one embodiment of the invention, the inhibitor is a molecule having a molecular weight from about 500 daltons to about 100 kilodaltons. In another embodiment of the invention, the inhibitor is an organic molecule or an inorganic molecule. In another embodiment of the invention, the inhibitor is a polypeptide or a nucleic acid molecule. In another embodiment of the invention, the inhibitor is soluble receptor for advanced glycation endproduct. In another embodiment of the invention, the inhibitor is an antibody which specifically binds to receptor for advanced

-8-

glycation endproduct.

The invention also provides for a method for ameliorating neurovascular stress in a subject which comprises
5 administering to the subject an effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE), so as to increase cerebral blood flow in the subject, thereby ameliorating neurovascular stress in the subject.

10 In one embodiment of the invention, the inhibitor of receptor for advanced glycation endproduct (RAGE) is soluble receptor for advanced glycation endproduct (RAGE). In another embodiment of the invention, the neurovascular stress comprises cerebral amyloid angiopathy. In another embodiment
15 of the invention, the neurovascular stress in the subject is caused by Alzheimer's disease, aging, Down's syndrome, head trauma, or stroke.

The invention also provides for a method for treating amyloid
20 angiopathy in a subject who suffers therefrom which comprises administering to the subject an effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) activity so as to increase cerebral blood flow in the subject and thereby treat amyloid angiopathy in the subject.

25

The present invention provides for a method for determining whether a compound increases cerebral blood flow in a subject which comprises: (a) administering the compound to a non-human animal which exhibits at least one of the following
30 characteristics: a correlative memory deficit, elevation of amyloid β in the brain of the non-human animal, or amyloid β plaques in the brain of the non-human animal; (b) determining whether the non-human animal has increased

-9-

cerebral blood flow when compared to cerebral blood flow in an identical non-human animal which was not administered the test compound; wherein an increase in cerebral blood flow indicates that the test compound increases cerebral blood flow in a subject.

In one embodiment of the invention, the non-human animal is a transgenic non-human animal. In another embodiment of the invention, the non-human animal is a transgenic mouse which over-expresses mutant human amyloid beta precursor protein. In another embodiment of the invention, the non-human animal is a transgenic non-human animal which is an animal model for Alzheimer's disease.

In one embodiment of the invention, the non-human animal is a Swiss transgenic mouse designated Tg APP sw+/-.

In one embodiment of the invention, the compound is a molecule having a molecular weight from about 500 daltons to about 100 kilodaltons. In one embodiment of the invention, the compound is an organic molecule or an inorganic molecule. In one embodiment of the invention, the compound is a polypeptide or a nucleic acid molecule.

25

The invention also provides for a method for ameliorating neurovascular stress in a subject which comprises administering to the subject an effective amount of an inhibitor of RAGE, so as to increase cerebral blood flow in the subject, thereby ameliorating neurovascular stress in the subject.

In one embodiment of the invention, the inhibitor of RAGE

-10-

is soluble RAGE. In another embodiment of the invention, the neurovascular stress comprises amyloid angiopathy. In another embodiment of the invention, the neurovascular stress is caused by Alzheimer's disease or aging of the subject.

5

The invention also provides for a method for treating amyloid angiopathy in a subject who suffers therefrom which comprises administering to the subject an effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE) activity so as to increase cerebral blood flow in the subject and thereby treat amyloid angiopathy in the subject.

The invention also provides for a method for treating cerebral amyloid angiopathy in a subject who suffers therefrom which comprises administering to the subject an effective amount of a compound determined to inhibit activity of receptor for advanced glycation endproducts (RAGE) in the method described hereinabove for determining whether a compound increases cerebral blood flow in a subject.

20

Definitions

"DNA sequence" is a linear sequence comprised of any combination of the four DNA monomers, i.e., nucleotides of adenine, guanine, cytosine and thymine, which codes for genetic information, such as a code for an amino acid, a promoter, a control or a gene product. A specific DNA sequence is one which has a known specific function, e.g., codes for a particular polypeptide, a particular genetic trait or affects the expression of a particular phenotype.

30

"Genotype" is the genetic constitution of an organism.

-11-

"Phenotype" is a collection of morphological, physiological and biochemical traits possessed by a cell or organism that results from the interaction of the genotype and the environment.

5

"Phenotypic expression" is the expression of the code of a DNA sequence or sequences which results in the production of a product, e.g., a polypeptide or protein, or alters the expression of the zygote's or the organisms natural
10 phenotype.

"Zygote" is a diploid cell having the potential for development into a complete organism. The zygote can result from parthenogenesis, nuclear transplantation, the merger of
15 two gametes by artificial or natural fertilization or any other method which creates a diploid cell having the potential for development into a complete organism. The origin of the zygote can be from either the plant or animal kingdom.

20

In the practice of any of the methods of the invention or preparation of any of the pharmaceutical compositions an "therapeutically effective amount" is an amount which is capable of alleviating the symptoms of the disorder of memory
25 or learning in the subject. Accordingly, the effective amount will vary with the subject being treated, as well as the condition to be treated. For the purposes of this invention, the methods of administration are to include, but are not limited to, administration cutaneously,
30 subcutaneously, intravenously, parenterally, orally, topically, or by aerosol.

By "nervous system-specific" is meant that expression of a

-12-

nucleic acid sequence occurs substantially in a nervous system tissue (for example, the brain or spinal cord). Preferably, the expression of the nucleic acid sequence in the nervous system tissue represents at least a 5-fold, more preferably, a 10-fold, and, most preferably, a 100-fold increase over expression in non-nervous system tissue.

The "non-human animals" of the invention include vertebrates such as rodents, non-human primates, sheep, dog, cow, amphibians, reptiles, etc. Preferred non-human animals are selected from the rodent family including rat and mouse, most preferably mouse.

The "transgenic non-human animals" of the invention are produced by introducing "transgenes" into the germline of the non-human animal.

Nucleotide and Amino Acid sequences of RAGE

The nucleotide and protein (amino acid) sequences for RAGE (both human and murine and bovine) are known. The following references which recite these sequences are incorporated by reference:

- Schmidt et al, J. Biol. Chem., 267:14987-97, 1992
Neeper et al, J. Biol. Chem., 267:14998-15004, 1992

RAGE sequences (DNA sequence and translation) from bovine, murine and homo sapien are listed hereinbelow. These sequences are available from GenBank as are other sequences of RAGE from other species:

LOCUS BOVRAGE 1426 bp mRNA MAM 09-DEC-1993 DEFINITION Cow

-13-

receptor for advanced glycosylation end products (RAGE) mRNA,
complete cds.

ACCESSION M91212 VERSION M91212.1 GI:163650

KEYWORDS RAGE; cell surface receptor.

5 SOURCE Bos taurus cDNA to mRNA. ORGANISM Bos taurus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
Euteleostomi; Mammalia; Eutheria; Cetartiodactyla;
Ruminantia; Pecora; Bovidea; Bovidae; Bovinae; Bos.
REFERENCE 1 (bases 1 to 1426) AUTHORS Neep, M.,
10 Schmidt, A.M., Brett, J., Yan, S.D., Wang, F., Pan, Y.C.,
Elliston, K., Stern, D. and Shaw, A. TITLE Cloning and
expression of a cell surface receptor for advanced
glycosylation end products of proteins
JOURNAL J. Biol. Chem. 267, 14998-15004 (1992)
15 MEDLINE 92340547 REFERENCE 2 (bases 1 to 1426) AUTHORS
Shaw, A. TITLE Direct Submission JOURNAL Submitted (15-APR-
1992) A. Shaw, Department of Cellular and Molecular Biology,
Merck Sharp and Dohme Research Laboratories, West Point, PA
19486
20 USAFEATURES Location/Qualifiers source 1..1426 /organism="Bos
taurus" /db_xref="taxon:9913" /tissue_type="lung" CDS
10..1260 /standard_name="RAGE" /codon_start=1
/product="receptor for advanced glycosylation end products"
/protein_id="AAA03575.1" /db_xref="GI:163651"
25 /translation="

MAAGAVVGAWMLVLSLGGTVTGDQNITARIGKPLVLNCKGAPKK
PPQQLWKLNTGRTEAWKVLSPQGDWDSVARVLPNGSLLLPAVGIQDEGTFRCRATS
30 RSGKETKSNYRVRVYQIPGKPEIVDPASELMAGVPNKVGTCVSEGGYPAGTLNWLLDG
KTLIPDGKGVSVKEETKRHPKTGLFTLHSELMVTPARGGALHPTFSCSFTPLPRRA
LHTAPIQLRVWSEHRGGEGPNVDAVPLKEVQLVVEPEGGAVAPGGTVTLTCEAPAQPP
PQIHWDKGRPLPLPPGPMLLLPEVGPEPDQGTYSVATHPSHGPPQESRAVSVTIETG

-14-

EEGTTAGSVEGPGLETLALTGLGILGGLGTVALLIGVIVWHRRRQRKGQERKVPENQEE
EEEEERAELNQPEEPEAAESSTGGP (SEQ ID NO:1)

polyA_signal 1406..1411 polyA_site 1426

5

BASE COUNT 322 a 429 c 440 g 235 t

ORIGIN

1 cggagaagga tggcagcagg ggcagtggtc ggagcctgga tgctagtctt
10 cagtctgggg 61 gggacagtca cgggggacca aaacatcaca gcccggatcg
ggaagccact ggtgctgaac 121 tgcaaggag cccccaagaa accaccccag
cagctggaat ggaaactgaa cacaggccgg 181 acagaagctt ggaaagtctt
gtctccccag ggagaccctt gggatagcgt ggctcgggtc 241 ctccccaacg
gctccctctt cctgccggct gttgggatcc aggatgaggg gactttccgg 301
15 tgccgggcaa cgagccggag cggaaaggag accaagtcta actaccgagt
ccgagtctat 361 cagattcctg ggaagccaga aattgttgat cctgcctctg
aactcatggc tgggtgtccc 421 aataagggtg ggacatgtgt gtccgagggg
ggctaccctg cagggactct taactggctc 481 ttggatggga aaactctgat
tcctgatggc aaaggagtgt cagtgaagga agagaccaag 541 agacacccaa
20 agacagggct tttcacgctc cattcggagc tgatggtgac ccagctcgg 601
ggaggagctc tccaccccac cttctcctgt agcttcaccc ctggccttcc
ccggcgccga 661 gccctgcaca cgccccccat ccagctcagg gtctggagtg
agcaccgagg tggggagggc 721 cccaacgtgg acgctgtgcc actgaaggaa
gtccagttgg tggtagagcc agaaggggga 781 gcagtagctc ctggtggtac
25 tgtgaccttg acctgtgaag cccccgcca gccccacct 841 caaatccact
ggatcaagga tggcaggccc ctgcccctt cccctggccc catgctgctc 901
ctcccagagg tagggcctga ggaccaggga acctacagtt gtgtggccac
ccatcccagc 961 catgggcccc aggagagccg tgctgtcagc gtcacgatca
tcgaaacagg cgaggagggg 1021 acgactgcag gctctgtgga agggccgggg
30 ctggaaaccc tagccctgac cctggggatc 1081 ctgggaggcc tggggacagt
cgccctgctc attgggttca tcgtgtggca tcgaaggcgg 1141 caacgcaaag
gacaggagag gaaggtcccc gaaaaccagg aggaggaaga ggaggagaga 1201
gcggaactga accagccaga ggagcccgag gcggcagaga gcagcacagg

-15-

agggccttga 1261 ggagcccacg gccagacccg atccatcagc cccttttctt
ttcccacact ctgttctggc 1321 cccagaccag ttctcctctg tataatctcc
agcccacatc tcccaaactt tcttccacaa 1381 ccagagcctc ccacaaaaag
tgatgagtaa acacctgcca cattta// (SEQ ID NO:2)

5

LOCUS HUMRAGE 1391 bp mRNA PRI 09-DEC-1993

DEFINITION Human receptor for advanced glycosylation end products (RAGE) mRNA,
partial cds.

ACCESSION M91211 VERSION M91211.1 GI:190845

10 KEYWORDS RAGE; cell surface receptor.

SOURCE Homo sapiens cDNA to mRNA.

ORGANISM Homo sapiens Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 1391)

15 AUTHORS Neeper,M., Schmidt,A.M., Brett,J., Yan,S.D., Wang,F., Pan,Y.C., Elliston,K.,
Stern,D. and Shaw,A.

TITLE Cloning and expression of a cell surface receptor for advanced glycosylation end
products of proteins

JOURNAL J. Biol. Chem. 267, 14998-15004 (1992)

20 MEDLINE 92340547

REFERENCE 2 (bases 1 to 1391)

AUTHORS Shaw,A.

TITLE Direct Submission

JOURNAL Submitted (15-APR-1992) A. Shaw, Department of Cellular and Molecular
25 Biology, Merck Sharp and Dohme Research Laboratories, West Point, PA 19486 USA

FEATURES Location/Qualifiers source 1..1391 /organism="Homo sapiens"
/db_xref="taxon:9606" /tissue_type="lung" CDS <1..1215 /standard_name="RAGE"
/codon_start=1 /product="receptor for advanced glycosylation end products"
/protein_id="AAA03574.1" /db_xref="GI:190846"

30

/translation="

-16-

GAAGTAVGAWVLVLSLWGAVVGAQNITARIGEPLVLKCKGAPKK
 PPQRLEWKLNTGRTEAWKVLSPQGGGPWDSVARVLPNGSLFLPAVGIQDEGIFRCRAM
 NRNGKETKSNYRVRVYQIPGKPEIVDSASELTAGVPNKVGTCTVSEGSYPAGTLSWHL
 GKPLVPNEKGVSVKEQTRRHPETGLFTLQSELMVTPARGGDPRTFSCSFSPGLPRHR
 5 ALRTAPIQPRVWEPVPLEEVQLVVEPEGGA VAPGGTVTLTCEVPAQPSQIHWMKDGV
 PLPLPPSPVLILPEIGPQDQGTYSVCVATHSSHGPQESRAVSISIIIEPGEEGPTAGSVG
 GSGLGTLALALGILGGLGTAALLIGVILWQRRQRERGEERKAPENQEEEEERAELNQSE
 EPEAGESSTGGP (SEQ ID NO:3)

10 polyA_signal 1368..1373 polyA_site 1391

BASE COUNT 305 a 407 c 418 g 261 t

ORIGIN

15 1 ggggcagccg gaacagcagt tggagcctgg gtgctggtcc tcagtctgtg gggggcagta
 61 gtaggtgctc aaaacatcac agcccgatt ggcgagccac tgggtctgaa gtgtaagggg
 121 gcccccaaga aaccaccca gcggtggaa tggaaactga acacaggccg gacagaagct
 181 tggaaaggtcc tgtctcccca gggaggaggc ccctgggaca gtgtggctcg tgccttccc
 241 aacggctccc tcttccttcc ggctgtcggg atccaggatg aggggatttt ccggtgcagg
 20 301 gcaatgaaca ggaatggaaa ggagaccaag tccaactacc gagtccgtgt ctaccagatt
 361 cctgggaagc cagaaattgt agattctgcc tctgaactca cggctggtgt tcccaataag
 421 gtggggacat gtgtgtcaga gggaagctac cctgcaggga ctcttagctg gcacttggat
 481 gggaaagcccc tgggtgcctaa tgagaaggga gtatctgtga aggaacagac caggagacac
 541 cctgagacag ggctcttcac actgcagtcg gagctaattg tgaccccgag ccggggagga
 25 601 gatccccgtc ccaccttctc ctgtagcttc agcccgaggc ttcccgaca ccgggccttg
 661 cgcacagccc ccatccagcc ccgtgtctgg gagcctgtgc ctctggagga ggtccaattg
 721 gtggtggagc cagaagggtg agcagtagct cctggtggaa ccgtaaccct gacctgtgaa
 781 gtccctgccc agccctctcc tcaaattcac tggatgaagg atggtgtgcc cttgcccctt
 841 cccccagcc ctgtgtgat cctccctgag atagggcctc aggaccaggg aacctacagc
 30 901 tgtgtggcca ccattccag ccacgggcc caggaaagcc gtgctgtcag catcagcatc
 961 atcgaaccag gcgaggagg gccaactgca ggctctgtgg gaggatcagg gctgggaact
 1021 ctagccctgg ccctggggat cctgggaggc ctggggacag ccgccctgct cattggggtc
 1081 atcttgtggc aaaggcggca acgcccagga gaggagagga agggcccaga aaaccaggag
 1141 gaagaggagg agcgtgcaga actgaatcag tcggagggaac ctgaggcagg cgagagtagt
 35 1201 actggagggc cttgaggggc ccacagacag atcccatcca tcagctccct tttctttttc
 1261 ccttgaactg ttctggcctc agaccaactc tctcctgtat aatctctctc ctgtataacc
 1321 ccaccttgcc aagctttctt ctacaaccag agccccccac aatgatgatt aaacacctga

-17-

1381 cacatcttgc a// (SEQ ID NO:4)

LOCUS MUSRECEP 1348 bp mRNA ROD 23-AUG-1994

DEFINITION Mouse receptor for advanced glycosylation end products (RAGE) gene,
5 complete cds.

ACCESSION L33412 VERSION L33412.1 GI:532208

KEYWORDS receptor for advanced glycosylation end products.

SOURCE Mus musculus (strain BALB/c, sub_species domesticus) (library: lambda gt10)
male adult lung cDNA to mRNA.

10 ORGANISM Mus musculus Eukaryota; Metazoa; Chordata; Craniata; Vertebrata;
Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE 1 (bases 1 to 1348)

AUTHORS Lundh,E.R., Morser,J., McClary,J. and Nagashima,M.

TITLE Isolation and characterization of cDNA encoding the murine and rat homologues
15 of the mammalian receptor for advanced glycosylation end products

JOURNAL Unpublished COMMENT On Aug 24, 1994 this sequence version replaced
gi:496146.

FEATURES Location/Qualifiers source 1..1348 /organism="Mus musculus"
/strain="BALB/c" /sub_species="domesticus" /db_xref="taxon:10090" /sex="male"
20 /tissue_type="lung" /dev_stage="adult" /tissue_lib="lambda gt10" gene 6..1217
/gene="RAGE" CDS 6..1217 /gene="RAGE" /codon_start=1 /product="receptor for
advanced glycosylation end products" /protein_id="AAA40040.1" /db_xref="GI:532209"

/translation="

25

MPAGTAARAWVLVLALWGAVAGGQNITARIGEPLVLSCKGAPKK
PPQQLWKLNTGRTEAWKVLSPQGGPWDSVAQILPNGSLLLPGTIVDEGTFRCRATN
RRGKEVKSNYRVRVYQIPGKPEIVDPASELTASVPNKVGTCTVSEGSYPAGTLSWHLDG
KLLIPDGKETLVKEETRRHPETGLFTLRSELTVIPTQGGTTHPTFSCSFSLGLPRRRP
30 LNTAPIQLRVREPGPPEGIQLLVEPEGGIVAPGGTVTLTCAISAQPPPQVHWIKDGAP
LPLAPSPVLLLPEVGHADGTYSCVATHPSHGPPQESPPVSIRVTETGDEGPAEGSVGE
SGLGTLALALGILGGLGVVALLVGAILWRKRQPRREERKAPESQEDEEEERAEINQSEE

- 18 -

AEMPENGAGGP (SEQ ID NO: 5)

polyA_site 1333

5 BASE COUNT 301 a 394 c 404 g 249 t

ORIGIN

```
1 gcacatgcc agcggggaca gcagctagag cctgggtgct ggttcttct ctatggggag
61 ctgtagctgg tggtcagaac atcacagccc ggattggaga gccacttgta ctaagctgta
10 121 agggggcccc taagaagccg cccagcagc tagaatggaa actgaacaca ggaagaactg
181 aagcttgaa ggtcctctct cccagggag gccctggga cagcgtggct caaatcctcc
241 ccaatgttc cctcctctt ccagccactg gaattgtcga tgaggggacg ttccggtgta
301 gggcaactaa caggcgaggg aaggaggtca agtccaacta ccgagtcga gtctaccaga
361 ttctgggaa gccagaaatt gtggatcctg cctctgaact cacagccagt gtccctaata
15 421 aggtggggac atgtgtgtct gagggagct accctgcagg gacccttagc tggcacttag
481 atgggaaact tctgattccc gatggcaaag aaacactcgt gaaggaagag accaggagac
541 accctgagac gggactctt acactgcgtg cagagctgac agtgatcccc acccaaggag
601 gaaccaccca tctaccttc tctgcagtt tcagcctggg cctccccgg cgagacccc
661 tgaacacagc ccctatcaa ctcgagtcg gggagcctgg gcctccagag ggcattcagc
20 721 tgttggttga gcctgaaggt ggaatagtcg ctcctgggtg gactgtgacc ttgacctgtg
781 ccctctctgc ccagccccct cctcaggtcc actggataaa ggatggtgca cccttcccc
841 tggctcccag ccctgtgctg ctctcctctg aggtggggca cgcggatgag ggcacctata
901 gctgcgtggc caccacccct agccacggac ctcaggaaag ccctcctgtc agcatcaggg
961 tcacagaaac cggcgatgag gggccagctg aaggctctgt gggtagtct gggctgggta
25 1021 cgctagccct ggccttgggg atcctgggag gcctgggagt agtagccctg ctctcgggg
1081 ctatcctgtg gcgaaaacga caaccaggc gtgaggagag gaaggcccc gaaagccagg
1141 aggatgagga ggaacgtgca gagctgaatc agtcagagga agcggagatg ccagagaatg
1201 gtgcccgggg accgtaagag caccagatc gagcctgtgt gatggcccta gagcagctcc
1261 cccacattcc atcccaattc ctcttgagg cacttcttc tccaaccaga gccacatga
30 1321 tcatgtctga gtaaacattt gatacggc// (SEQ ID NO: 6)
```

-19-

Inhibitors of RAGE:

Inhibitors of RAGE include any molecule which, when introduced into a cell or a subject, is capable of inhibiting the biological activity of RAGE. For example, one such inhibitor would be able to inhibit the activity of RAGE as described: the activity of transcytosis of amyloid beta peptides across the blood brain barrier within a subject.

Examples of an inhibitor of RAGE activity are soluble RAGE, an antibody which specifically binds to RAGE, a truncated version of RAGE which is capable of acting as a competitive inhibitor of RAGE. A fragment of RAGE which includes the amyloid beta peptide binding portion of RAGE and introduced into the cell or subject as a soluble polypeptide. Other types of inhibitors would be known to one of skill in the art. For example, a small molecule could be prepared which mimics the amyloid beta peptide binding region of RAGE and administered alone as an inhibitor.

20

Pharmaceutical compositions and Carriers

As used herein, the term "suitable pharmaceutically acceptable carrier" encompasses any of the standard pharmaceutically accepted carriers, such as phosphate buffered saline solution, water, emulsions such as an oil/water emulsion or a triglyceride emulsion, various types of wetting agents, tablets, coated tablets and capsules. An example of an acceptable triglyceride emulsion useful in intravenous and intraperitoneal administration of the compounds is the triglyceride emulsion commercially known as Intralipid®.

-20-

Typically such carriers contain excipients such as starch, milk, sugar, certain types of clay, gelatin, stearic acid, talc, vegetable fats or oils, gums, glycols, or other known excipients. Such carriers may also include flavor and color
5 additives or other ingredients.

This invention also provides for pharmaceutical compositions including therapeutically effective amounts of protein compositions and compounds together with suitable diluents,
10 preservatives, solubilizers, emulsifiers, adjuvants and/or carriers useful in treatment of neuronal degradation due to aging, a learning disability, or a neurological disorder. Such compositions are liquids or lyophilized or otherwise dried formulations and include diluents of various buffer
15 content (e.g., Tris-HCl., acetate, phosphate), pH and ionic strength, additives such as albumin or gelatin to prevent absorption to surfaces, detergents (e.g., Tween 20, Tween 80, Pluronic F68, bile acid salts), solubilizing agents (e.g., glycerol, polyethylene glycerol), anti-oxidants (e.g.,
20 ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the compound, complexation with metal ions, or incorporation of
25 the compound into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc, or onto liposomes, micro emulsions, micelles, unilamellar or multi lamellar vesicles, erythrocyte ghosts, or spheroplasts. Such compositions will influence
30 the physical state, solubility, stability, rate of in vivo release, and rate of in vivo clearance of the compound or composition. The choice of compositions will depend on the physical and chemical properties of the compound.

-21-

Controlled or sustained release compositions include formulation in lipophilic depots (e.g., fatty acids, waxes, oils). Also comprehended by the invention are particulate compositions coated with polymers (e.g., poloxamers or
5 poloxamines) and the compound coupled to antibodies directed against tissue-specific receptors, ligands or antigens or coupled to ligands of tissue-specific receptors. Other embodiments of the compositions of the invention incorporate particulate forms protective coatings, protease inhibitors
10 or permeation enhancers for various routes of administration, including parenteral, pulmonary, nasal and oral.

Portions of the compound of the invention may be "labeled" by association with a detectable marker substance (e.g.,
15 radiolabeled with ^{125}I or biotinylated) to provide reagents useful in detection and quantification of compound or its receptor bearing cells or its derivatives in solid tissue and fluid samples such as blood, cerebral spinal fluid or urine.

20 When administered, compounds are often cleared rapidly from the circulation and may therefore elicit relatively short-lived pharmacological activity. Consequently, frequent injections of relatively large doses of bioactive compounds may be required to sustain therapeutic efficacy. Compounds
25 modified by the covalent attachment of water-soluble polymers such as polyethylene glycol, copolymers of polyethylene glycol and polypropylene glycol, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinylpyrrolidone or polyproline are known to exhibit substantially longer half-
30 lives in blood following intravenous injection than do the corresponding unmodified compounds (Abuchowski et al., 1981; Newmark et al., 1982; and Katre et al., 1987). Such modifications may also increase the compound's solubility in

-22-

aqueous solution, eliminate aggregation, enhance the physical and chemical stability of the compound, and greatly reduce the immunogenicity and reactivity of the compound. As a result, the desired *in vivo* biological activity may be achieved by the administration of such polymer-compound adducts less frequently or in lower doses than with the unmodified compound.

Attachment of polyethylene glycol (PEG) to compounds is particularly useful because PEG has very low toxicity in mammals (Carpenter et al., 1971). For example, a PEG adduct of adenosine deaminase was approved in the United States for use in humans for the treatment of severe combined immunodeficiency syndrome. A second advantage afforded by the conjugation of PEG is that of effectively reducing the immunogenicity and antigenicity of heterologous compounds. For example, a PEG adduct of a human protein might be useful for the treatment of disease in other mammalian species without the risk of triggering a severe immune response. The compound of the present invention capable of alleviating symptoms of a cognitive disorder of memory or learning may be delivered in a microencapsulation device so as to reduce or prevent an host immune response against the compound or against cells which may produce the compound. The compound of the present invention may also be delivered microencapsulated in a membrane, such as a liposome.

Polymers such as PEG may be conveniently attached to one or more reactive amino acid residues in a protein such as the alpha-amino group of the amino terminal amino acid, the epsilon amino groups of lysine side chains, the sulfhydryl groups of cysteine side chains, the carboxyl groups of aspartyl and glutamyl side chains, the alpha-carboxyl group

-23-

of the carboxy-terminal amino acid, tyrosine side chains, or to activated derivatives of glycosyl chains attached to certain asparagine, serine or threonine residues.

5 Numerous activated forms of PEG suitable for direct reaction with proteins have been described. Useful PEG reagents for reaction with protein amino groups include active esters of carboxylic acid or carbonate derivatives, particularly those in which the leaving groups are N-hydroxysuccinimide, p-
10 nitrophenol, imidazole or 1-hydroxy-2-nitrobenzene-4-sulfonate. PEG derivatives containing maleimido or haloacetyl groups are useful reagents for the modification of protein free sulfhydryl groups. Likewise, PEG reagents containing amino hydrazine or hydrazide groups are useful for
15 reaction with aldehydes generated by periodate oxidation of carbohydrate groups in proteins.

In one embodiment the compound of the present invention is associated with a pharmaceutical carrier which includes a
20 pharmaceutical composition. The pharmaceutical carrier may be a liquid and the pharmaceutical composition would be in the form of a solution. In another embodiment, the pharmaceutically acceptable carrier is a solid and the composition is in the form of a powder or tablet. In a
25 further embodiment, the pharmaceutical carrier is a gel and the composition is in the form of a suppository or cream. In a further embodiment the active ingredient may be formulated as a part of a pharmaceutically acceptable transdermal patch.

30

Transgenic Technology and Methods

The following U.S. Patents are hereby incorporated by

-24-

reference: U.S. Patent No. 6,025,539, IL-5 transgenic mouse;
U.S. Patent No. 6,023,010, Transgenic non-human animals
depleted in a mature lymphocytic cell-type; U.S. Patent No.
6,018,098, In vivo and in vitro model of cutaneous
5 photoaging; U.S. Patent No. 6,018,097, Transgenic mice
expressing human insulin; U.S. Patent No. 6,008,434, Growth
differentiation factor-11 transgenic mice; U.S. Patent No.
6,002,066; H2-M modified transgenic mice; U.S. Patent No.
5,994,618, Growth differentiation factor-8 transgenic mice;
10 U.S. Patent No. 5,986,171, Method for examining
neurovirulence of polio virus, U.S. Patent No. 5,981,830,
Knockout mice and their progeny with a disrupted hepsin gene;
U.S. Patent No. 5,981,829, .DELTA.Nur77 transgenic mouse;
U.S. Patent No. 5,936,138; Gene encoding mutant L3T4 protein
15 which facilitates HIV infection and transgenic mouse
expressing such protein; U.S. Patent No. 5,912,411, Mice
transgenic for a tetracycline-inducible transcriptional
activator; U.S. Patent No. 5,894,078, Transgenic mouse
expressing C-100 app.

20

The methods used for generating transgenic mice are well
known to one of skill in the art. For example, one may use
the manual entitled "Manipulating the Mouse Embryo" by Brigid
Hogan et al. (Ed. Cold Spring Harbor Laboratory) 1986.

25

See for example, Leder and Stewart, U.S. Patent No. 4,736,866
for methods for the production of a transgenic mouse.

For sometime it has been known that it is possible to carry
30 out the genetic transformation of a zygote (and the embryo
and mature organism which result therefrom) by the placing
or insertion of exogenous genetic material into the nucleus
of the zygote or to any nucleic genetic material which

-25-

ultimately forms a part of the nucleus of the zygote. The genotype of the zygote and the organism which results from a zygote will include the genotype of the exogenous genetic material. Additionally, the inclusion of exogenous genetic material in the zygote will result in a phenotype expression of the exogenous genetic material.

The genotype of the exogenous genetic material is expressed upon the cellular division of the zygote. However, the phenotype expression, e.g., the production of a protein product or products of the exogenous genetic material, or alterations of the zygote's or organism's natural phenotype, will occur at that point of the zygote's or organism's development during which the particular exogenous genetic material is active. Alterations of the expression of the phenotype include an enhancement or diminution in the expression of a phenotype or an alteration in the promotion and/or control of a phenotype, including the addition of a new promoter and/or controller or supplementation of an existing promoter and/or controller of the phenotype.

The genetic transformation of various types of organisms is disclosed and described in detail in U.S. Pat. No. 4,873,191, issued Oct. 10, 1989, which is incorporated herein by reference to disclose methods of producing transgenic organisms. The genetic transformation of organisms can be used as an in vivo analysis of gene expression during differentiation and in the elimination or diminution of genetic diseases by either gene therapy or by using a transgenic non-human mammal as a model system of a human disease. This model system can be used to test putative drugs for their potential therapeutic value in humans.

-26-

The exogenous genetic material can be placed in the nucleus of a mature egg. It is preferred that the egg be in a fertilized or activated (by parthenogenesis) state. After the addition of the exogenous genetic material, a complementary haploid set of chromosomes (e.g., a sperm cell or polar body) is added to enable the formation of a zygote. The zygote is allowed to develop into an organism such as by implanting it in a pseudopregnant female. The resulting organism is analyzed for the integration of the exogenous genetic material. If positive integration is determined, the organism can be used for the in vivo analysis of the gene expression, which expression is believed to be related to a particular genetic disease.

Attempts have been made to study a number of different types of genetic diseases utilizing such transgenic animals. Attempts related to studying Alzheimer's disease are disclosed within published PCT application WO89/06689 and PCT application WO89/06693, both published on Jul. 27, 1989, which published applications are incorporated herein by reference to disclose genetic sequences coding for Alzheimer's .beta.-amyloid protein and the incorporation of such sequences into the genome of transgenic animals.

Embryonal target cells at various developmental stages can be used to introduce transgenes. Different methods are used depending on the stage of development of the embryonal target cell. The zygote is the best target for micro-injection. In the mouse, the male pronucleus reaches the size of approximately 20 micrometers in diameter which allows reproducible injection of 1-2 pl of DNA solution. The use of zygotes as a target for gene transfer has a major advantage in that in most cases the injected DNA will be incorporated

-27-

into the host gene before the first cleavage (Brinster, et al. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 4438-4442). As a consequence, all cells of the transgenic non-human animal will carry the incorporated transgene. This will in general
5 also be reflected in the efficient transmission of the transgene to offspring of the founder since 50% of the germ cells will harbor the transgene. Microinjection of zygotes is the preferred method for incorporating transgenes in practicing the invention.

10

Retroviral infection can also be used to introduce transgene into a non-human animal. The developing non-human embryo can be cultured in vitro to the blastocyst stage. During this time, the blastomeres can be targets for retroviral infection
15 (Jaenich, R. (1976) Proc. Natl. Acad. Sci U.S.A. 73, 1260-1264). Efficient infection of the blastomeres is obtained by enzymatic treatment to remove the zona pellucida (Hogan, et al. (1986) in Manipulating the Mouse Embryo, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). The viral
20 vector system used to introduce the transgene is typically a replication-defective retrovirus carrying the transgene (Jahner, et al. (1985) Proc. Natl. Acad. Sci. U.S.A. 82, 6927-6931; Van der Putten, et al. (1985) Proc. Natl. Acad. Sci U.S.A. 82, 6148-6152). Transfection is easily and
25 efficiently obtained by culturing the blastomeres on a monolayer of virus-producing cells (Van der Putten, supra; Stewart, et al. (1987) EMBO J. 6, 383-388). Alternatively, infection can be performed at a later stage. Virus or virus-producing cells can be injected into the blastocoele (Jahner,
30 D., et al. (1982) Nature 298, 623-628). Most of the founders will be mosaic for the transgene since incorporation occurs only in a subset of the cells which formed the transgenic non-human animal. Further, the founder may contain various

-28-

retroviral insertions of the transgene at different positions in the genome which generally will segregate in the offspring. In addition, it is also possible to introduce transgenes into the germ line, albeit with low efficiency, 5 by intrauterine retroviral infection of the midgestation embryo (Jahner, D. et al. (1982) supra).

A third type of target cell for transgene introduction is the embryonal stem cell (ES). ES cells are obtained from pre- 10 implantation embryos cultured in vitro and fused with embryos (Evans, M. J., et al. (1981) Nature 292, 154-156; Bradley, M. O., et al. (1984) Nature 309, 255-258; Gossler, et al. (1986) Proc. Natl. Acad. Sci U.S.A. 83, 9065-9069; and Robertson, et al. (1986) Nature 322, 445-448). Transgenes can 15 be efficiently introduced into the ES cells by DNA transfection or by retrovirus-mediated transduction. Such transformed ES cells can thereafter be combined with blastocysts from a non-human animal. The ES cells thereafter colonize the embryo and contribute to the germ line of the 20 resulting chimeric animal. For review see Jaenisch, R. (1988) Science 240, 1468-1474.

As used herein, a "transgene" is a DNA sequence introduced into the germline of a non-human animal by way of human 25 intervention such as by way of the above described methods.

The disclosures of publications referenced in this application in their entireties are hereby incorporated by reference into this application in order to more fully 30 describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein.

-29-

This invention is illustrated in the Experimental Details section which follows. These sections are set forth to aid in an understanding of the invention but are not intended to, and should not be construed to, limit in any way the
5 invention as set forth in the claims which follow thereafter.

-30-

EXPERIMENTAL DETAILSExample 1: Receptor for Advanced Glycation Endproduct (RAGE)-
dependent neurovascular dysfunction caused by amyloid- β
5 peptide

Amyloid-beta peptides ($A\beta$) are important in the pathogenesis of Alzheimer's dementia. We show that RAGE mediates $A\beta$ transport across the blood-brain barrier (BBB) in mice
10 followed by its rapid neuronal uptake, cytokine response, oxidant stress and reductions in the cerebral blood flow (CBF). Antagonizing RAGE in transgenic mice that overexpress mutant human $A\beta$ precursor protein restored the CBF and ameliorated neurovascular stress. In Alzheimer's brains,
15 vascular expression of RAGE was associated with $A\beta$ accumulation. We suggest that RAGE at the BBB is a potential target for inhibiting vascular accumulation of $A\beta$ and for limiting cellular stress and ischemic changes in Alzheimer's dementia.

20

Deposition of $A\beta$ in the CNS occurs during normal aging and is accelerated by Alzheimer's Disease (AD). ¹⁻⁴ $A\beta$ is implicated in neuropathology of AD and related disorders. ¹⁻⁴ $A\beta$ peptides have neurotoxic properties *in vitro* ⁵⁻⁷ and *in*
25 *vivo*, ⁸⁻¹⁰ and induce neuronal oxidant stress directly and indirectly by activating microglia. ¹¹⁻¹³ $A\beta$ generates superoxide radicals in brain endothelium, ¹⁴ and at higher concentrations may damage endothelial cells. ¹⁵ Recent studies from our and other laboratories suggest a major role
30 of the blood-brain barrier (BBB) in determining the concentrations of $A\beta$ in the CNS. ¹⁶⁻²⁵ The BBB controls the entry of plasma-derived $A\beta$ and its binding transport proteins into the CNS, and regulates the levels of brain-derived $A\beta$

-31-

via clearance mechanisms.

RAGE (receptor for advanced glycation end-product), a multiligand receptor in the immunoglobulin superfamily binds free A β in the nanomolar range, and mediates pathophysiological cellular responses when occupied by glycated ligands, A β , S100/calgranulins or serum amyloid A.^{24,26-28} RAGE is up-regulated on microglia and vascular endothelium in AD brains.^{29,30} We have recently reported that RAGE may be involved in transport of A β across human brain endothelial monolayers.^{24,31} Our current study demonstrates that RAGE mediates *in vivo* transcytosis of A β ₁₋₄₀ and A β ₁₋₄₂ across the BBB in mice. RAGE-dependent BBB transport of A β was coupled to its rapid neuronal uptake, induction of cellular stress and transient, but significant suppression of cerebral blood flow (CBF). Antagonizing RAGE in transgenic mice that overexpress mutant human A β precursor protein (APP) restored the CBF and ameliorated cellular stress. In Alzheimer's brains, vascular expression of RAGE was associated with A β accumulation. These data support the possibility that inhibiting RAGE at the BBB may limit vascular accumulation of A β and reduce cellular stress and ischemic changes in Alzheimer's dementia.

RAGE mediates *in vivo* transcytosis of A β across the BBB

RAGE-dependent binding to brain microvessels (Fig. 1a) and transport across the BBB (Fig. 1b) of human and mouse A β ₁₋₄₀, and somewhat slower, but significant RAGE-dependent BBB transport of A β ₁₋₄₂ (Fig. 1b) and absence of its significant binding to microvessels (Fig. 1a) were found in mice (shown in Fig. 1) and guinea pigs. A β transport into brain was significantly inhibited by 65% to 85% by circulating α -RAGE

-32-

IgG (5-40 μ g/kg) and abolished by sRAGE. Several other molecular reagents including fucoidan (a ligand for the scavenger receptor type A), anti- β 1-integrin antibodies, or RHDS peptide (5-9 sequence of A β) did not affect either BBB
5 transport or binding of A β (Figs. 1a and b). Although A β peptides were partially metabolized during their transport across the BBB (i.e., \leq 50% for 10 min), significant and rapid RAGE-dependent neuronal uptake of circulating A β was observed after the BBB transport (Fig. 1e).

10

Circulating A β and RAGE-dependent neurovascular stress

Transport of A β ₁₋₄₀ across the BBB was associated with an early
15 cellular stress response that preceded changes in the CBF. The expression of TNF- α mRNA and protein on different cells in brain parenchyma, including neurons and brain endothelium was evident after 15 min of transport of circulating A β across the BBB (Fig. 2a). Treatment with circulating sRAGE
20 (Fig. 2a) or α -RAGE IgG abolished A β -induced TNF- α expression. A β transport across the BBB resulted in rapid neuronal expression of IL-6 (Fig. 2b) and HO-1 (Fig 3c), and these effects were abolished by either α -RAGE IgG (Fig. 2 b and c) or sRAGE, supporting the concept that RAGE-dependent
25 A β BBB transport initiates cellular stress in brain. RAGE-dependent A β -induced cellular stress was found either after cerebral arterial or systemic intravenous administration of A β , and persisted in brain for few hours. Fig. 2d illustrates expression of TNF- α , IL-6 and HO-1 in brain 2 hrs after i.v.
30 administration of A β ₁₋₄₀ at low nanomolar level.

Systemic administration of A β ₁₋₄₀ (either human or murine) at low nanomolar concentrations resulted in time-dependent

-33-

decrease in the CBF, but did not affect systemic arterial blood pressure (Fig. 3a). Reductions in the CBF were detectable after 20-30 min of A β administration, and maximal decrease in the CBF was observed between 40-60 min. CBF changes were completely antagonized by circulating α -RAGE at 40 μ g/ml (Fig. 3b). A β -induced cerebral vasospasm was antagonized by α -RAGE in a dose-dependent manner, was abolished by sRAGE, but was not affected by an irrelevant antibody (Fig. 3c).

10

RAGE blockade restores the CBF in Tg APP sw+/- mice

Fig. 4a shows significant decrease in basal CBF values in 9 months old Tg APPsw+/- mice compared to age-matched control mice as determined by laser Doppler flowmetry, and confirmed by quantitative autoradiographic analysis. There was no difference in the arterial blood pressure between wild type and Tg APPsw+/- mice (Fig. 4a). Infusion of α -RAGE dramatically increased the CBF in Tg APPsw+/- mice (Fig. 4b), and the effect was maximal between 60-120 min after systemic administration of α -RAGE. An irrelevant IgG did not affect the CBF in Tg APPsw+/- animals (Fig. 4b). Systemic administration of α -RAGE ameliorated cellular stress in brain of 9 month old Tg APPsw+/- mice, as indicated by moderate reduction in expression of TNF- α , IL-6 and HO-1 (Fig. 4c). Expression of RAGE on brain microvessels was enhanced in Tg APPsw+/- mice (Fig. 4d left), and increased vascular expression of RAGE was associated with accumulation of A β in AD brains (Fig 4d right).

30

Discussion

These data demonstrate that RAGE has an important role in A β -mediated uptake at the BBB and its transport into the central

-34-

nervous system, as well as A β -mediated cellular perturbation.

The first set of studies employed synthetic A β infused in to wild-type mice, and the results apply to acute exposure of
5 vasculature to A β .

This invention provides the following methods:

A method for blockading RAGE, with either sRAGE or anti-RAGE
10 IgG which thereby,

- suppresses binding to and uptake of A β in relation to the vessel wall

- inhibits A β -induced cell stress in the vasculature and
15 in neurons, consequent to systemic infusion of A β

Such an experimental model, although artificial, may be directly relevant to head trauma, stroke and other disorders in which there are acute elevations of A β .

20

The second set of studies uses the Hsiao mice (reference for these is Hisao K, Chapman P, Nilsen S, Eckman C, Harigaya Y, Younkin S, Yang F, Cole G: correlative memory deficits, A β elevation, and amyloid plaques in transgenic mice. Science
25 274:99, 1996). These experiments suggests that chronic exposure of vasculature to A β results in RAGE-dependent vasoconstriction- thus, a RAGE blocker would be expected to increase cerebral blood flow in patients with increased levels of amyloid-beta peptide (at least when A β is in the
30 blood or blood vessel wall). These mice were made using the prion promoter, which expresses amyloid precursor protein in neurons and glial cells, predominately, but some seems to get into the vasculature as well. These mice are considered a

-35-

model of Alzheimer's disease. Thus, increasing cerebral blood flow in these mice could be interpreted as increasing cerebral blood flow in the setting of Alzheimer's disease. Decreased blood flow would be considered an adverse effect for cerebral function, thus, increasing blood flow would be considered (at least indirectly) neuroprotective.

The second set of studies actually is more powerful in terms of its implications since the mice are considered a model of Alzheimer's-type pathology.

Methods

Synthetic peptides: A β ₁₋₄₀ and A β ₁₋₄₂ human forms, and A β ₁₋₄₀ murine form were synthesized at the W M Keck Facility at Yale University using solid-phase tBOC(N-tert-butyloxycarbonyl)-chemistry, purified by HPLC, and the final products lyophilized and characterized by analytical reverse-phase HPLC, amino acid analysis, laser desorption mass spectrometry, as we previously described.^{22,24} Stock solutions were prepared in DMSO to assure monomeric species, and kept at -80°C until use.

Radioiodination: of A β was carried out with Na[¹²⁵I] and Iodobeads (Pierce), and the resulting components resolved by HPLC.^{22,24}

Animals and tissue preparation: TgAPPsw+/- mice (bearing the double mutation Lys670Asn, Met671Leu) 9 months of age were in a mixed C57B6/SJL background, as were age-matched wild type control mice were used throughout the study. Animals were screened for the presence of the APP transgenes by PCR as described.³⁵ For histology, mice received intraperitoneal (i.p.) pentobarbital (150 mg/kg) and were perfused

-36-

transcardially with 0.1M PBS (pH 7.4) at 4°C. The right hemisphere was immersion-fixed in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) at 4°C overnight. The brain was cryoprotected in 30% sucrose in PBS at 4°C, and then fixed
5 in paraformaldehyde as above at 4°C.

Cerebral blood flow measurement:. CBF was monitored by Laser Doppler Flowmetry (LDF, Transonic BLF21, NY) as we described.
³⁶ LDF probes (0.8 mm diameter) were positioned on the
10 cortical surface 2 mm posterior to the bregma, both 3 and 6 mm to each side of midline. The CBF was also determined by quantitative autoradiography using ¹⁴C-iodoantipyrine (IAP) using recently reported modified method in the whole mouse.
³⁷ Briefly, 0.15 μ Ci ¹⁴C-IAP was injected i.p. and animals
15 sacrificed after 2 min. Blood from the frozen heart was sampled to obtain the final blood ¹⁴C-IAP level. Frozen brains were coronally sectioned at 20 μ m and exposed to autoradiographic film along with radioactive ¹⁴C standards. After a 5 day exposure, the film was developed and the
20 resulting images analyzed by quantitative autoradiography to determine levels of ¹⁴C-IAP in individual brain regions. The CBF was calculated as reported: ^{37,40} $F = -\lambda \ln (1 - C_{IN(T)} / \lambda C_{PL}) / T$, where F is the rate of flow per unit mass (\cdot^{-1}), $C_{IN(T)}$ is activity in unit weight of brain at time T, C_{PL} is the
25 concentration of ¹⁴C-IAP in the blood, and λ is the distribution ratio of ¹⁴C-IAP between brain and the perfusion medium or blood at the steady state, i.e. 0.8.

A β (4 nM/l) or vehicle were administered via femoral vein (n
30 = 5 per group). α -RAGE, sRAGE etc.

Brain perfusion model. This model has been extensively used to determine peptide and protein binding to and transport across the BBB. ^{22,23,38,39} For intra-arterial brain perfusion
35 technique mice were anesthetized with i.p. ketamine (0.5

-37-

mg/kg) and xylazine (5 mg/kg), and the right common carotid artery isolated and connected to an extracorporeal perfusion circuit via fine polyethylene cannula (PE10). Details of the extracorporeal perfusion circuit were as reported elsewhere.

5 ^{22,23,38,39} At the start of the perfusion, the contralateral common carotid artery was ligated, and both jugular veins severed to allow free drainage of the perfusate. Brains were perfused with oxygenated perfusion medium at a flow rate of 1 ml/min by peristaltic pump. The perfusion medium consisted

10 of 20% sheep red blood cells (oxygen carrier) suspended in mock plasma containing 48 g/L dextran (FW 70 000) to maintain colloid osmotic pressure, and electrolytes and D-glucose (196 mg/dl) at concentrations corresponding to normal mouse plasma levels. Perfusion pressure and animal's own arterial blood

15 pressure were continuously monitored. Blood gasses pO₂, pCO₂ and pH and electrolytes in the arterial inflow and in animal's own blood were monitored. All physiological parameters were kept within the normal range as we described.

^{22,23,38,39}

20

Injection of radioisotopes for transport studies. [¹²⁵I]-A β , ^{99m}Tc-albumin or ¹⁴C-labeled inulin were infused into arterial inflow at a rate of 0.1 ml/min typically within 10 min for

25 transport studies (corresponds to the linear phase of A β uptake). When the effects of different unlabeled molecular reagents were tested, those were injected 5 min prior to tracers injection and than simultaneously with radiolabeled ligands. At predetermined times within 10 min mice were

30 sacrificed by decapitation, and brain tissue prepared for radioactivity analysis. TCA and HPLC analysis as we described were used to determine molecular forms of uptake of radiolabeled A β by the BBB. ^{22,23} Capillary-depletion technique was used to separate microvascular pellet from capillary-

-38-

depleted brain to quantify in vivo binding to microvessels vs. transport into brain parenchyma, as we reported.^{22,23}

Mathematical modeling for transport studies. We have reported details of mathematical analysis elsewhere.^{22,23,38,39} The uptake values for ¹²⁵I- A β were based on the amount of intact molecule as determined by the TCA and HPLC analysis. The rate of entry (K_{IN}) is computed from eq. 1: $d[C_{IN (TEST-MOLECULE)} - C_{IN (ALBUMIN)}]/dt = K_{IN} C_{PL} - K_{OUT} [C_{IN (TEST-MOLECULE)} - C_{IN (ALBUMIN)}]$, where K_{OUT} is exit or efflux transfer coefficient, and R is the steady state or equilibrium ratio. Eq. 1 is integrated to give $[C_{IN (TEST-MOLECULE)} - C_{IN (ALBUMIN)}]/C_{PL} = R (1 - e^{-K_{OUT} T})$ (eq. 2). R is the steady state ratio, and the ratio K_{IN}/K_{OUT} at infinite time, and T is infusion time. Numerical values for K_{OUT} may be obtained from the slope of the plot of $\ln (R - [C_{IN (TEST-MOLECULE)} - C_{IN (ALBUMIN)}]/C_{PL})$ (eq. 3) against T , using the equation $K_{OUT} = -\ln(R - [C_{IN (TEST-MOLECULE)} - C_{IN (ALBUMIN)}]/C_{PL})/T$ (eq. 4). Finally, the value for K_{IN} is derived by substituting the number for K_{OUT} in: $K_{IN} = R K_{OUT}$ (eq. 5). When tracer uptake remains linear over studied period of time, the exist constant approaches zero, and $K_{IN} = d[C_{IN (TEST-MOLECULE)} - C_{IN (ALBUMIN)}]/dt C_{PL}$. The K_{IN} represents the fraction of circulating radioactive ligands that is taken up intact by 1 g of brain from 1 ml of plasma in 1 min, and is the same as the PS product if K_{IN} or PS \ll CBF,³⁹ a condition satisfied by A β . Advanced graphics software and the MLAB mathematical modeling system (as above) will be used to obtain graphic plots and compute transfer coefficients.

Immunocytochemical analysis: for TNF- α , IL-6 and HO-1 in brains of wild type mice and TgAPPsw+/- mice was performed using standard techniques, as described (26). Briefly, fresh-frozen, acetone-fixed brain sections of wild type and

-39-

TgAPPsw+/- mice were stained with anti-TNF- α IgG (Santa Cruz), anti-IL-6 IgG (Santa Cruz and anti-HO-1 IgG (StressGen) as primary antibodies. The extent and intensity of staining in cellular elements was quantitated using the Universal Imaging System and NIH imaging systems. The relative intensity of cellular staining in control brain sections was compared to treated brains. Routine control sections included deletion of primary antibody, deletion of secondary antibody and the use of an irrelevant primary antibody.

Statistical analysis. Data from the proposed studies were analyzed by multifactorial analysis of variance (ANOVA) that ranged from one-way to three-way ANOVA. Each ANOVA included an analysis of residuals as a check on the required assumptions of normally distributed errors with constant variance. In the event the required assumptions were not satisfied, data transformations were considered. Appropriate multiple comparisons were included as a part of each analysis. For pair-wise comparisons, the Tukey method was used, and for comparisons with a control group we used Dunnett's test.

Example 2: RAGE at the Blood Brain Barrier Mediates Neurovascular Dysfunction Caused by Amyloid β_{1-40} peptide

Amyloid-beta peptides ($A\beta$) are important in the pathogenesis of Alzheimer's dementia. We found that the receptor for advanced glycation end products (RAGE) mediates *in vivo* transcytosis of circulating $A\beta_{1-40}$ across the blood-brain barrier (BBB) in mice. In an acute model in mice, blood to brain transport of $A\beta_{1-40}$ (1-4 nM final plasma concentration) was coupled to its rapid neuronal uptake, cytokine responses

-40-

including enhanced production of tumor necrosis factor - α mRNA and protein and interleukin-6, neuronal oxidant stress (e.g. increased expression of hemoxygenase-1), and sustained reductions in cerebral blood flow (CBF). $A\beta$ -induced cellular stress and cerebral vasospasm were blocked by circulating α -RAGE (40 μ g/ml). In a chronic model, in 9-month old transgenic Tg APP sw +/- mice, CBF was significantly reduced by 63% in comparison to age-matched controls, this reduction was reversible by circulating α -RAGE in a dose-dependent fashion (10-40 μ g/ml). In brains of subjects suffering from Alzheimer's disease, increased vascular expression of RAGE was associated with peri-vascular accumulation of $A\beta$, vascular and peri-vascular accumulation of proteins with nitrosylated amino-acid residues and increased expression of endothelial nitric oxide (NO) synthase. We conclude that vascular dysfunction caused by $A\beta$ via RAGE at the BBB may contribute to ischemic changes and neurovascular injury in Alzheimer's dementia.

References

1. Selkoe DJ. The cell biology of beta-amyloid precursor
5 protein and presenilin in Alzheimer's disease. Trends Cell
Biol 1998; 8:447-53.
2. Younkin SG. The role of A beta 42 in Alzheimer's disease.
J Physiol (Paris) 1998; 92:289-92.
3. Roses AD. Alzheimer disease: a model of gene mutations and
10 susceptibility polymorphisms for complex psychiatric
diseases. Amer J Med Gen 1998; 81:49-57.
4. Hardy J, Duff K, Hardy KG, Perez-Tur J, Hutton M. Genetic
dissection of Alzheimer's disease and related dementias:
amyloid and its relationship to tau. Nat Neurosci 1998;
15 1:355-8.
5. Pike CJ, Burdick D, Walencewicz AJ, Glabe CJ, Cotman CW.
Neurodegeneration induced by β -amyloid peptides in vitro: the
role of peptide assembly state. J Neurosci 1993;13:1676-87.
6. Ueda K, Fukui , Kageyama H. Amyloid beta protein-induced
20 neuronal cell death: neurotoxic properties of aggregated
amyloid beta protein. Brain Res 1994;639:240-4.
7. Lorenzo A, Yankner BA. Beta-amyloid neurotoxicity requires
fibril formation and is inhibited by congo red. Proc Natl
Acad Sci USA 1994;91:12243-7.
- 25 8. Kowall NW, Beal MF, Busciglio J, Duffy LK, Yankner BA.
An in vivo model for the neurodegenerative effects of β
amyloid and protection by substance P. Proc Natl Acad Sci
USA 1991;88:7247-51.
9. Frautschy SA, Baird A, Cole GM. Effects of injected
30 Alzheimers beta-amyloid cores in rat brain. Proc Natl Acad
Sci USA 1991;88:8362-6.
10. Kowall NW, McKee AC, Yankner BA, Beal MF. In vivo
neurotoxicity of beta-amyloid [β (1-40)] and the β (25-35)
fragment. Neurobiol Aging 1992;13:537-42.
- 35 11. Smith MA, Sayre LM, Monnier VM, Perry G. Radical AGEing

-42-

- in Alzheimer's disease. Trends Neurosci 1995;18:172-6.
12. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE and amyloid- β peptide neurotoxicity in
5 Alzheimer's disease. Nature 1996;382:685-91.
13. McGeer PL, McGeer EG. The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Rev 1995;21:195-218.
14. Thomas T, Thomas G, McLendo C, Sutton T, Mullan M. β -
10 Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996;380:115-8.
15. Blanc EM, Toboreck M, Mark RJ, Hennig B, Mattson MP. Amyloid β -peptide induces cell monolayer albumin permeability, impairs glucose transport, and induces
15 apoptosis in vascular endothelial cells. J Neurochem 1997;68(5):1870-81.
16. Zlokovic BV. Can blood-brain barrier play a role in the development of cerebral amyloidosis and Alzheimer's disease pathology. Neurobiol Dis 1997;4(1):23-6.
- 20 17. Zlokovic BV, et al. Clearance of amyloid-b-peptide from brain: transport or metabolism? Nature Med. 6(7), 718-719
18. Maness LM, Banks WA, Podlisny MB, Selkoe DJ, Kastin AJ. Passage of human amyloid- β protein 1-40 across the murine blood-brain barrier. Life Sci 1994;55:1643-50.
- 25 19. Poduslo JF, Curran GL, Haggard JJ, Biere AL, Selkoe DJ. Permeability and residual plasma volume of human, Dutch variant, and rat amyloid β -protein 1-40 at the blood-brain barrier. Neurobiol Dis 1997;4(1):27-34.
20. Ghilardi JR, Catton M, Stimson ER, Rogers S, Walker LC, Maggio JE, Mantyh PW. Intra-arterial infusion of [125I]A β 1-
30 40 labels amyloid deposits in the aged primate brain in vivo. Neuroreport 1996;7:2607-11.
21. Mackic JB, Weiss MH, Miao W, Ghiso J, Calero M, Bading J, Frangione B, Zlokovic BV. Cerebrovascular accumulation and
35 increased blood-brain barrier permeability to circulating

-43-

- Alzheimer's amyloid- β peptide in aged squirrel monkey with cerebral amyloid angiopathy. *J Neurochem* 1998;70:210-5.
22. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, Frangione B, Ghiso J. Glycoprotein 5 330/megalin: Probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer's disease amyloid β at the blood-brain and blood-cerebrospinal fluid barriers. *Proc Natl Acad Sci USA* 1996;93:4229-36.
23. Martel CL, Mackic JB, Matsubara E, Governale S, Miguel 10 C, Miao W, McComb JG, Frangione B, Ghiso J, Zlokovic BV. Isoform-specific effects of apolipoproteins E2, E3, E4 on cerebral capillary sequestration and blood-brain barrier transport of circulating Alzheimer's amyloid β . *J Neurochem* 1997;69:1995-2004.
24. Mackic JB, Stins M, McComb JG, Calero M, Ghiso J, Kim KS, 15 Yan SD, Stern D, Schmidt AM, Frangione B, Zlokovic BV. Human blood-brain barrier receptors for Alzheimer's amyloid- β ₁₋₄₀: asymmetrical binding, endocytosis and transcytosis at the apical side of brain microvascular endothelial cell 20 monolayer. *J Clin Invest* 1998;102:734-743.
25. Gherzi-Egea JF, Gorevic PD, Ghiso J, Frangione BF, Patlak CS, Fenstermacher JD. Fate of cerebrospinal fluid-borne amyloid β -peptide: rapid clearance into blood and appreciable accumulation by cerebral arteries *J Neurochem* 1996;67:880- 25 83.
26. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, Kindy M. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. *Nat Med* 2000;6:643-51.
27. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y, Avila 30 C, Kambham N, Bierhaus A, Nawroth P, Neurath MF, Slaterry T, Beach D, McClary J, Nagashima M, Morser J, Stern D, Schmidt AM. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. *Cell* 35 1999;97:889-901.
28. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slaterry T,

-44-

- Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, Schmidt AM. RAGE and amyloid- β peptide neurotoxicity in Alzheimer's disease. *Nature* 1996;382:685-91.
29. Krieger M, Herz J. Structures and functions of
5 multiligand lipoprotein receptors: macrophage scavenger
receptors and LDL receptor-related protein (LRP). *Annu Rev
Biochem* 1994;63:601-637.
30. Lucarelli M, Gennarelli M, Cardeli R, Cardeli R, Novelli
G, Scarpa S, Dallapiccola B, Strom R. Expression of
10 receptors for native and chemically modified low-density
lipoproteins in brain microvessels. *FEBS Lett* 1997;401:53-8.
31. Schmidt AM, Hasu M, Popov D, Zhang JH, Chen J, Yan SD,
Brett J, Cao R, Kuwabara K, Gostache G, Simionescu N,
Simionescu M, Stern D. Receptor for advanced glycation end
15 products (AGE) has a central role in vessel wall interactions
and gene activation in response to circulating AGE proteins.
Proc Natl Acad Sci USA 1994;91:8807-11.
35. Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan
Am, Chang LK, Sun Y, Paul SM. In Vivo expression of
20 apolipoprotein E reduces amyloid- β -deposition in a mouse
model of Alzheimer's Disease. *J Clin Invest* 1999; 103:R15-21.
36. Tabrizi et Zlokovic, BV., ATVB, 1999
37. Maeda K, Mies G, Olah L, Hossmann KA. Quantitative
measurement of local cerebral blood flow in the anesthetized
25 mouse using intraperitoneal [14 C]iodoantipyrine injection and
final arterial heart blood sampling. *J Cereb Blood Flow Metab*
2000;20:10-4.
38. Zlokovic BV. Cerebrovascular permeability to peptides:
manipulations of transport systems at the blood-brain
30 barrier. *Pharm Res* 1995; 12(10): 1395-1406.
39. Zlokovic BV, Jovanovic S, Miao W, Samara S, Verma S,
Farrell CL. Differential regulation of leptin transport by
the choroid plexus and blood-brain barrier and high affinity
transport systems for entry into hypothalamus and across the
35 blood-cerebrospinal fluid barrier. *Endocrinology*
2000;141:1434-41.

-45-

40. Zlokovic BV, Begley DJ, Djuricic BM, Mitrovic DM.
Measurement of solute transport across the blood-brain
barrier in the perfused guinea pig brain: method and
application to N-methyl-alpha- aminoisobutyric acid. J
5 Neurochem 1986;46:1444-51.

-46-

What is claimed is:

1. A method for decreasing cerebral vasoconstriction in a subject suffering from chronic or acute cerebral amyloid angiopathy which comprises administering to the subject an inhibitor of receptor for advanced glycation endproduct (RAGE) in an effective amount to inhibit transcytosis of amyloid β peptides across the blood-brain barrier in the subject, thereby decreasing cerebral vasoconstriction in the subject.
2. The method of claim 1, wherein the subject is a transgenic non-human animal or a human.
3. The method of claim 2, wherein the non-human animal is a transgenic mouse which over-expresses mutant human amyloid beta precursor protein.
4. The method of claim 1, wherein the subject suffers from Alzheimer's disease.
5. The method of claim 1, wherein the chronic cerebral amyloid angiopathy is due to Alzheimer's disease, Down's syndrome, aging or angiopathy.
6. The method of claim 1, wherein the acute cerebral amyloid angiopathy is due to head trauma, or stroke.
7. The method of claim 1, wherein the inhibitor is a molecule having a molecular weight from about 500 daltons to about 100 kilodaltons.
8. The method of claim 1, wherein the inhibitor is an

-47-


organic molecule or an inorganic molecule.

9. The method of claim 1, wherein the inhibitor is a polypeptide or a nucleic acid molecule.
- 5 10. The method of claim 1, wherein the inhibitor is soluble receptor for advanced glycation endproduct.
- 10 11. The method of claim 1, wherein the inhibitor is an antibody which specifically binds to receptor for advanced glycation endproduct.
- 15 12. A method for ameliorating neurovascular stress in a subject which comprises administering to the subject an effective amount of an inhibitor of receptor for advanced glycation endproduct (RAGE), so as to increase cerebral blood flow in the subject, thereby ameliorating neurovascular stress in the subject.
- 20 13. The method of claim 12, wherein the inhibitor of receptor for advanced glycation endproduct (RAGE) is soluble receptor for advanced glycation endproduct (RAGE).
- 25 14. The method of claim 12, wherein the neurovascular stress comprises cerebral amyloid angiopathy.
15. The method of claim 12, wherein the neurovascular stress in the subject is caused by Alzheimer's disease, aging, Down's syndrome, head trauma, or stroke.
- 30 16. A method for treating amyloid angiopathy in a subject who suffers therefrom which comprises administering to

-48-

the subject an effective amount of an inhibitor of
receptor for advanced glycation endproduct (RAGE)
activity so as to increase cerebral blood flow in the
subject and thereby treat amyloid angiopathy in the
5 subject.

Figure 1A-C



2/8

Figure 1D




FIGURE 1E-1F





Figure 2A

4/8



5/8

Figure 2B-C





Figure 2D

6/8



7/8

FIGURE 3A-3C




FIGURE 4A-4D



1

SEQUENCE LISTING

<110> The Trustees of Columbia University in the City of New York

<120> A METHOD TO INCREASE CEREBRAL BLOOD FLOW IN AMYLOID
ANGIOPATHY

<130> 0575/62097-PCT

<140> Not Yet Known

<141> 2001-08-14

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 416

<212> PRT

<213> Bos Taurus

<400> 1

Met	Ala	Ala	Gly	Ala	Val	Val	Gly	Ala	Trp	Met	Leu	Val	Leu	Ser	Leu
1				5					10					15	

Gly	Gly	Thr	Val	Thr	Gly	Asp	Gln	Asn	Ile	Thr	Ala	Arg	Ile	Gly	Lys
			20					25					30		

Pro	Leu	Val	Leu	Asn	Cys	Lys	Gly	Ala	Pro	Lys	Lys	Pro	Pro	Gln	Gln
		35					40					45			

Leu	Glu	Trp	Lys	Leu	Asn	Thr	Gly	Arg	Thr	Glu	Ala	Trp	Lys	Val	Leu
	50					55					60				

Ser	Pro	Gln	Gly	Asp	Pro	Trp	Asp	Ser	Val	Ala	Arg	Val	Leu	Pro	Asn
65					70					75				80	

Gly	Ser	Leu	Leu	Leu	Pro	Ala	Val	Gly	Ile	Gln	Asp	Glu	Gly	Thr	Phe
			85						90					95	

Arg	Cys	Arg	Ala	Thr	Ser	Arg	Ser	Gly	Lys	Glu	Thr	Lys	Ser	Asn	Tyr
			100					105					110		

Arg	Val	Arg	Val	Tyr	Gln	Ile	Pro	Gly	Lys	Pro	Glu	Ile	Val	Asp	Pro
			115				120					125			

Ala	Ser	Glu	Leu	Met	Ala	Gly	Val	Pro	Asn	Lys	Val	Gly	Thr	Cys	Val
			130			135						140			

Ser Glu Gly Gly Tyr Pro Ala Gly Thr Leu Asn Trp Leu Leu Asp Gly
 145 150 155 160
 Lys Thr Leu Ile Pro Asp Gly Lys Gly Val Ser Val Lys Glu Glu Thr
 165 170 175
 Lys Arg His Pro Lys Thr Gly Leu Phe Thr Leu His Ser Glu Leu Met
 180 185 190
 Val Thr Pro Ala Arg Gly Gly Ala Leu His Pro Thr Phe Ser Cys Ser
 195 200 205
 Phe Thr Pro Gly Leu Pro Arg Arg Arg Ala Leu His Thr Ala Pro Ile
 210 215 220
 Gln Leu Arg Val Trp Ser Glu His Arg Gly Gly Glu Gly Pro Asn Val
 225 230 235 240
 Asp Ala Val Pro Leu Lys Glu Val Gln Leu Val Val Glu Pro Glu Gly
 245 250 255
 Gly Ala Val Ala Pro Gly Gly Thr Val Thr Leu Thr Cys Glu Ala Pro
 260 265 270
 Ala Gln Pro Pro Pro Gln Ile His Trp Ile Lys Asp Gly Arg Pro Leu
 275 280 285
 Pro Leu Pro Pro Gly Pro Met Leu Leu Leu Pro Glu Val Gly Pro Glu
 290 295 300
 Asp Gln Gly Thr Tyr Ser Cys Val Ala Thr His Pro Ser His Gly Pro
 305 310 315 320
 Gln Glu Ser Arg Ala Val Ser Val Thr Ile Ile Glu Thr Gly Glu Glu
 325 330 335
 Gly Thr Thr Ala Gly Ser Val Glu Gly Pro Gly Leu Glu Thr Leu Ala
 340 345 350
 Leu Thr Leu Gly Ile Leu Gly Gly Leu Gly Thr Val Ala Leu Leu Ile
 355 360 365
 Gly Val Ile Val Trp His Arg Arg Arg Gln Arg Lys Gly Gln Glu Arg
 370 375 380

Lys Val Pro Glu Asn Gln Glu Glu Glu Glu Glu Glu Arg Ala Glu Leu
 385 390 395 400

Asn Gln Pro Glu Glu Pro Glu Ala Ala Glu Ser Ser Thr Gly Gly Pro
 405 410 415

<210> 2

<211> 1426

<212> DNA

<213> Bos Taurus

<400> 2

cggagaagga tggcagcagg ggcagtggtc ggagcctgga tgctagtcct cagtctgggg 60
 gggacagtca cgggggacca aaacatcaca gcccggatcg ggaagccact ggtgctgaac 120
 tgcaaggagag cccccaagaa accaccccag cagctggaat ggaaactgaa cacaggccgg 180
 acagaagctt ggaaagtcct gtctccccag ggagaccctt gggatagcgt ggctcgggtc 240
 ctccccaacg gctccctcct cctgccggct gttgggatcc aggatgaggg gactttccgg 300
 tgccgggcaa cgagccggag cggaaaggag accaagtcta actaccgagt ccgagtcctat 360
 cagattcctg ggaagccaga aattgttgat cctgcctctg aactcatggc tgggtgtcccc 420
 aataagggtg ggacatgtgt gtccgagggg ggctaccctg cagggactct taactggctc 480
 ttggatggga aaactctgat tcctgatggc aaaggagtgt cagtgaagga agagaccaag 540
 agacacccaa agacagggct ttccacgctc cattcggagc tgatggtgac ccagctcgg 600
 ggaggagctc tccaccccac cttctcctgt agcttcaccc ctggccttcc ccggcgccga 660
 gccctgcaca cggcccccat ccagctcagg gtctggagtg agcaccgagg tggggagggc 720
 cccaacgtgg acgctgtgcc actgaaggaa gtccagttgg tggtagagcc agaaggggga 780
 gcagtagctc ctggtggtac tgtgacctg acctgtgaag ccccgccca gccccacct 840
 caaatccact ggatcaagga tggcaggccc ctgcccttc cccctggccc catgctgctc 900

ctcccagagg tagggcctga ggaccagga acctacagtt gtgtggccac ccatcccagc 960
catgggcccc aggagagccg tgctgtcagc gtcacgatca tcgaaacagg cgaggagggg 1020
acgactgcag gctctgtgga agggccgggg ctggaaaccc tagccctgac cctgggggac 1080
ctgggaggcc tggggacagt cgccctgctc attgggggtca tcgtgtggca tcgaaggcgg 1140
caacgcaaag gacaggagag gaaggtcccg gaaaaccagg aggaggaaga ggaggagaga 1200
gcggaactga accagccaga ggagcccag ggggcagaga gcagcacagg agggccttga 1260
ggagcccacg gccagaccg atccatcagc cctttttctt ttcccacact ctgttctggc 1320
cccagaccag ttctcctctg tataatctcc agccacatc tcccaaactt tcttcacaa 1380
ccagagcctc ccacaaaaag tgatgagtaa acacctgccca cattta 1426

<210> 3

<211> 404

<212> PRT

<213> Human

<400> 3

Gly Ala Ala Gly Thr Ala Val Gly Ala Trp Val Leu Val Leu Ser Leu
1 5 10 15

Trp Gly Ala Val Val Gly Ala Gln Asn Ile Thr Ala Arg Ile Gly Glu
20 25 30

Pro Leu Val Leu Lys Cys Lys Gly Ala Pro Lys Lys Pro Pro Gln Arg
35 40 45

Leu Glu Trp Lys Leu Asn Thr Gly Arg Thr Glu Ala Trp Lys Val Leu
50 55 60

Ser Pro Gln Gly Gly Gly Pro Trp Asp Ser Val Ala Arg Val Leu Pro
65 70 75 80

Asn Gly Ser Leu Phe Leu Pro Ala Val Gly Ile Gln Asp Glu Gly Ile
85 90 95

Phe Arg Cys Arg Ala Met Asn Arg Asn Gly Lys Glu Thr Lys Ser Asn
100 105 110

Tyr Arg Val Arg Val Tyr Gln Ile Pro Gly Lys Pro Glu Ile Val Asp
 115 120 125

Ser Ala Ser Glu Leu Thr Ala Gly Val Pro Asn Lys Val Gly Thr Cys
 130 135 140

Val Ser Glu Gly Ser Tyr Pro Ala Gly Thr Leu Ser Trp His Leu Asp
 145 150 155 160

Gly Lys Pro Leu Val Pro Asn Glu Lys Gly Val Ser Val Lys Glu Gln
 165 170 175

Thr Arg Arg His Pro Glu Thr Gly Leu Phe Thr Leu Gln Ser Glu Leu
 180 185 190

Met Val Thr Pro Ala Arg Gly Gly Asp Pro Arg Pro Thr Phe Ser Cys
 195 200 205

Ser Phe Ser Pro Gly Leu Pro Arg His Arg Ala Leu Arg Thr Ala Pro
 210 215 220

Ile Gln Pro Arg Val Trp Glu Pro Val Pro Leu Glu Glu Val Gln Leu
 225 230 235 240

Val Val Glu Pro Glu Gly Gly Ala Val Ala Pro Gly Gly Thr Val Thr
 245 250 255

Leu Thr Cys Glu Val Pro Ala Gln Pro Ser Pro Gln Ile His Trp Met
 260 265 270

Lys Asp Gly Val Pro Leu Pro Leu Pro Pro Ser Pro Val Leu Ile Leu
 275 280 285

Pro Glu Ile Gly Pro Gln Asp Gln Gly Thr Tyr Ser Cys Val Ala Thr
 290 295 300

His Ser Ser His Gly Pro Gln Glu Ser Arg Ala Val Ser Ile Ser Ile
 305 310 315 320

Ile Glu Pro Gly Glu Glu Gly Pro Thr Ala Gly Ser Val Gly Gly Ser
 325 330 335

Gly Leu Gly Thr Leu Ala Leu Ala Leu Gly Ile Leu Gly Gly Leu Gly
 340 345 350

Thr Ala Ala Leu Leu Ile Gly Val Ile Leu Trp Gln Arg Arg Gln Arg
 355 360 365

Arg Gly Glu Glu Arg Lys Ala Pro Glu Asn Gln Glu Glu Glu Glu Glu
 370 375 380

Arg Ala Glu Leu Asn Gln Ser Glu Glu Pro Glu Ala Gly Glu Ser Ser
 385 390 395 400

Thr Gly Gly Pro

<210> 4

<211> 1391

<212> DNA

<213> Human

<400> 4

ggggcagccg gaacagcagt tggagcctgg gtgctggtcc tcagtctgtg gggggcagta 60
 gtaggtgctc aaaacatcac agcccgatt ggcgagccac tggctgtgaa gtgtaagggg 120
 gcccccaaga aaccaccca gcggctggaa tggaactga acacaggccg gacagaagct 180
 tggaaggtcc tgtctcccca gggaggaggc ccctgggaca gtgtggctcg tgtccttccc 240
 aacggctccc tcttccttcc ggctgtcggg atccaggatg aggggatttt ccggtgcagg 300
 gcaatgaaca ggaatggaaa ggagaccaag tccaactacc gagtccgtgt ctaccagatt 360
 cctgggaagc cagaaattgt agattctgcc tctgaactca cggtgtgtgt tcccaataag 420
 gtggggacat gtgtgtcaga gggaagctac cctgcaggga ctcttagctg gcacttggat 480
 gggaagcccc tgggtgcctaa tgagaagggg gtatctgtga aggaacagac caggagacac 540
 cctgagacag ggctcttcac actgcagtcg gagctaattg tgacccagc ccggggagga 600
 gatccccgtc ccaccttctc ctgtagcttc agccaggcc ttccccgaca ccgggccttg 660
 cgcacagccc ccattccagc ccgtgtctgg gagcctgtgc ctctggagga ggtccaattg 720
 gtggtggagc cagaaggtgg agcagtagct cctggtggaa ccgtaaccct gacctgtgaa 780
 gtccctgccc agccctctcc tcaaatecac tggatgaagg atggtgtgcc cttgccccctt 840
 cccccagcc ctgtgtgat cctccctgag atagggcctc aggaccaggg aacctacagc 900
 tgtgtggcca ccattccag ccacgggccc caggaaagcc gtgctgtcag catcagcatc 960

atcgaaccag gcgaggaggg gccaaactgca ggctctgtgg gaggatcagg gctgggaact 1020
 ctagccctgg ccctggggat cctgggagggc ctggggacag ccgccctgct cattgggggtc 1080
 atcttgtggc aaaggcggca acgcccagga gaggagagga aggccccaga aaaccaggag 1140
 gaagaggagg agcgtgcaga actgaatcag tcggaggaaac ctgaggcagg cgagagtagt 1200
 actggagggc cttgaggggc ccacagacag atcccatcca tcagctccct tttctttttc 1260
 ccttgaactg ttctggcctc agaccaactc tctcctgtat aatctctctc ctgtataacc 1320
 ccaccttgcc aagcttttct ctacaaccag agccccccac aatgatgatt aaacacctga 1380
 cacatcttgc a 1391

<210> 5

<211> 403

<212> PRT

<213> Mouse

<400> 5

Met Pro Ala Gly Thr Ala Ala Arg Ala Trp Val Leu Val Leu Ala Leu
 1 5 10 15

Trp Gly Ala Val Ala Gly Gly Gln Asn Ile Thr Ala Arg Ile Gly Glu
 20 25 30

Pro Leu Val Leu Ser Cys Lys Gly Ala Pro Lys Lys Pro Pro Gln Gln
 35 40 45

Leu Glu Trp Lys Leu Asn Thr Gly Arg Thr Glu Ala Trp Lys Val Leu
 50 55 60

Ser Pro Gln Gly Gly Pro Trp Asp Ser Val Ala Gln Ile Leu Pro Asn
 65 70 75 80

Gly Ser Leu Leu Leu Pro Ala Thr Gly Ile Val Asp Glu Gly Thr Phe
 85 90 95

Arg Cys Arg Ala Thr Asn Arg Arg Gly Lys Glu Val Lys Ser Asn Tyr
 100 105 110

Arg Val Arg Val Tyr Gln Ile Pro Gly Lys Pro Glu Ile Val Asp Pro
 115 120 125

Ala	Ser	Glu	Leu	Thr	Ala	Ser	Val	Pro	Asn	Lys	Val	Gly	Thr	Cys	Val	
130							135				140					
Ser	Glu	Gly	Ser	Tyr	Pro	Ala	Gly	Thr	Leu	Ser	Trp	His	Leu	Asp	Gly	
145					150					155					160	
Lys	Leu	Leu	Ile	Pro	Asp	Gly	Lys	Glu	Thr	Leu	Val	Lys	Glu	Glu	Thr	
				165					170					175		
Arg	Arg	His	Pro	Glu	Thr	Gly	Leu	Phe	Thr	Leu	Arg	Ser	Glu	Leu	Thr	
			180					185					190			
Val	Ile	Pro	Thr	Gln	Gly	Gly	Thr	Thr	His	Pro	Thr	Phe	Ser	Cys	Ser	
		195					200					205				
Phe	Ser	Leu	Gly	Leu	Pro	Arg	Arg	Arg	Pro	Leu	Asn	Thr	Ala	Pro	Ile	
210						215					220					
Gln	Leu	Arg	Val	Arg	Glu	Pro	Gly	Pro	Pro	Glu	Gly	Ile	Gln	Leu	Leu	
225					230					235					240	
Val	Glu	Pro	Glu	Gly	Gly	Ile	Val	Ala	Pro	Gly	Gly	Thr	Val	Thr	Leu	
				245				250						255		
Thr	Cys	Ala	Ile	Ser	Ala	Gln	Pro	Pro	Pro	Gln	Val	His	Trp	Ile	Lys	
			260				265						270			
Asp	Gly	Ala	Pro	Leu	Pro	Leu	Ala	Pro	Ser	Pro	Val	Leu	Leu	Leu	Pro	
		275					280					285				
Glu	Val	Gly	His	Ala	Asp	Glu	Gly	Thr	Tyr	Ser	Cys	Val	Ala	Thr	His	
		290				295					300					
Pro	Ser	His	Gly	Pro	Gln	Glu	Ser	Pro	Pro	Val	Ser	Ile	Arg	Val	Thr	
305					310					315					320	
Glu	Thr	Gly	Asp	Glu	Gly	Pro	Ala	Glu	Gly	Ser	Val	Gly	Glu	Ser	Gly	
				325					330					335		
Leu	Gly	Thr	Leu	Ala	Leu	Ala	Leu	Gly	Ile	Leu	Gly	Gly	Leu	Gly	Val	
			340					345					350			
Val	Ala	Leu	Leu	Val	Gly	Ala	Ile	Leu	Trp	Arg	Lys	Arg	Gln	Pro	Arg	
		355					360					365				
Arg	Glu	Glu	Arg	Lys	Ala	Pro	Glu	Ser	Gln	Glu	Asp	Glu	Glu	Glu	Arg	
		370				375					380					

Ala Glu Leu Asn Gln Ser Glu Glu Ala Glu Met Pro Glu Asn Gly Ala
 385 390 395 400

Gly Gly Pro

<210> 6

<211> 1347

<212> DNA

<213> Mouse

<400> 6

gcaccatgcc agcggggaca gcagctagag cctgggtgct ggttcttgct ctatggggag 60
 ctgtagctgg tggtcagaac atcacagccc ggattggaga gccacttggt ctaagctgta 120
 agggggcccc taagaagccg cccagcagc tagaatggaa actgaacaca ggaagaactg 180
 aagcttgga ggtcctctct cccagggag gccctggga cagcgtggct caaatcctcc 240
 ccaatggttc cctcctcctt ccagccactg gaattgtcga tgaggggacg ttccggtgtc 300
 gggcaactaa caggcgaggg aaggaggtca agtccaacta ccgagtccga gtctaccaga 360
 ttcttgaggaa gccagaaatt gtggatcctg cctctgaact cacagccagt gtccctaata 420
 aggtggggac atgtgtgtct gagggaagct accctgcagg gacccttagc tggcacttag 480
 atgggaaact tctgattccc gatggcaaag aaacactcgt gaaggaagag accaggagac 540
 accctgagac gggactcttt aactgcggt cagagctgac agtgatcccc acccaaggag 600
 gaaccaccca tctaccttc tctgcagtt tcagcctggg ccttccccgg cgcagacccc 660
 tgaacacagc ccctatccaa ctccgagtca gggagcctgg gcctccagag ggcattcagc 720
 tgttggttga gcctgaaggt ggaatagtcg ctcttggtgg gactgtgacc ttgacctgtg 780
 ccatctctgc ccagccccct cctcaggtcc actggataaa ggatggtgca cccttgcccc 840
 tggctcccag ccctgtgctg ctctccctg aggtggggca cgcggatgag ggcacctata 900
 gctgcgtggc caccacccct agccacggac ctcaggaaag ccctcctgtc agcatcaggg 960
 tcacagaaac cggcgatgag gggccagctg aaggctctgt gggtgagtct gggctgggta 1020

cgctagccct ggccttgggg atcctgggag gcctgggagt agtagccctg ctcgtcgggg 1080
ctatcctgtg gcgaaaacga caaccaggc gtgaggagag gaaggccccg gaaagccagg 1140
aggatgagga ggaacgtgca gagctgaatc agtcagagga agcggagatg ccagagaatg 1200
gtgccggggg accgtaagag caccagatc gagcctgtgt gatggcccta gagcagctcc 1260
cccacattcc atoccaattc ctccttgagg cacttccttc tccaaccaga gccacatga 1320
ccatgctgag taaacatttg atacggc 1347

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/25416

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 15/63, 15/85, 15/87, 15/00, 15/09, 15/63, 15/70, 15/74, 5/00, 5/02; A01N 43/04; A61K 31/70; G01N 33/00; A01K 67/00, 67/033, 67/027;
 US CL : 435/455, 463, 320.1, 325; 514/44; 800/3, 8, 9, 11, 13, 18, 21, 22, 25

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/455, 463, 320.1, 325; 514/44; 800/3, 8, 9, 11, 13, 18, 21, 22, 25

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
 WEST, CAPLUS, MEDLINE, BIOSIS, LIFESCI, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WALL, R.J. Transgenic Livestock: Progress and Prospects for the Future. 1 January 1996, Vol. 45, pages 57-68, see especially entire document.	1-16
A	HOUEBINE, L.-M. Production of Pharmaceutical Proteins from Transgenic Animals. 31 May 1994, Vol 34, pages 269-287, especially entire article.	1-16
A	HAMMER, R. et al. Genetic Engineering of Mammalian Embryos. July 1986, Vol 63, pages 269-278, especially entire document.	1-16
A	EBERT, K. et al. A Moloney MLV-Rat Somatotropin Fusion Gene Produces Biologically Active Somatotropin in a Transgenic Pig. March 1998, Vol 2. No. 3, pages 277-283, especially entire document.	1-16
A	MULLINS, L. et al. Perspective Series: Molecular Medicine in Genetically Engineered Animals. April 1996, Vol 98. No. 11, pages S37-S40, especially entire document.	1-16
A	KAPPEL, C.A. et al. Regulating Gene Expression in Transgenic Animals. October 1992, Vol 3. No. 5, pages 548-553, especially entire document.	1-16
A	STROJEK, R.M. et al. The Use of Transgenic Animal Techniques for Livestock Improvement. 1988, Vol 10, pages 221-246, especially entire document.	1-16



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	
"A" document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E" earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O" document referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent family
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

27 September 2001 (27.09.2001)

Date of mailing of the international search report

27 DEC 2001

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

Karen M. Hauda

Telephone No. 703-308-0196